

1. HENZE E, SCHELBERT HR, COLLINS JD, et al: Lymphoscintigraphy with Tc-99m labeled dextran. *J Nucl Med* 23: 923-929, 1982
2. ASPERGEN K, STRAND SE, PERSON BRR: Quantitative lymphoscintigraphy for detection of metastases to the internal mammary lymph nodes. Biokinetics of ^{99m}Tc -sulfur colloid uptake and correlation with microscopy. *Acta Radiol Oncol* 17:17-26, 1978
3. STRAND SE, PERSON BRR: Quantitative lymphoscintigraphy I: Basic concepts for optimal uptake of radiocolloids in the parasternal lymph nodes of rabbits. *J Nucl Med* 20:1038-1046, 1979
4. ARNAUD D, DILHUYDY JM, BASSE-CATHALINAT B: Exploration des chaines mammaires internes au moyen de la lymphoscintigraphie isotopique. *J Franc Biophys Med Nucl* 2:99-104, 1977
5. MANJI MF: Internal mammary lymphoscintigraphy in breast carcinoma: possible significance in relation to current treatment. *J Can Assoc Radiol* 33:10-14, 1982
6. EGE GN: Internal mammary lymphoscintigraphy in breast carcinoma: A study of 1072 patients. *Int J Radiat Oncol Biol Phys* 2:755-761, 1977
7. BERGQVIST L, STRAND SE, PERSON BRR: Particle sizing and biokinetics of interstitial lymphoscintigraphic agents. *Semin Nucl Med*, 1983 (in press).
8. DWORKIN HJ: Potential for lymphoscintigraphy. *J Nucl Med* 23:936-938, 1982

Re: Teaching Editorial. Potential for Lymphoscintigraphy

As a Teaching Editorial, I find this article somewhat confusing with regard to the subject of lymph node imaging by a variety of modalities (1). The first paragraph is unsettling for the critical reader. For example, in radiocontrast lymphangiography (RCL) if water soluble medium is used to examine lymphatics of the upper and lower limbs whereas oily contrast media are used for groin, pelvic, abdominal and axillary lymph nodes, how does one deliver the oily media to these respective lymph node groups without introducing it into the relevant lower and upper limbs for which water soluble contrast media are indicated? Such a contradictory statement deserves further elaboration.

The properties, qualities, and applications of $^{99m}\text{TcSb}_2\text{S}_3$ have been underestimated. This agent has been used in our institution for ten years in over 9,000 studies and is currently in use in multiple centers in the U.S.A., Europe, Australia, New Zealand and South Africa. The clinical applications have not been as narrow as implied, and this agent has found a use *not* in the therapy of metastatic breast carcinoma but in the assessment, treatment planning and follow-up of patients with all stages of breast cancer as well as in patients with pelvic neoplasms and malignant melanoma. If the market for $^{99m}\text{TcSb}_2\text{S}_3$, compared with other pharmaceuticals has been limited, this reflects the prevalence of malignancy compared with the broad range of other pathological conditions investigated in our departments.

The experience of those personally involved in carrying out lymphoscintigraphy on a regular basis does not support the assertions of problems associated with particle size or reagent instability and batch-to-batch variability.

The objective of lymphoscintigraphy as it has developed over the past decade has been to assess the status of lymph nodes at risk from neoplastic infiltration and not specifically to establish the temporal interval for lymphatic visualization. Individual discrete lymph nodes can be distinguished with radiocolloid, comparison between different lymph nodes is possible, and patterns indicative of abnormality can be recognized. The same cannot be said cur-

rently about images obtained with Tc-99m dextran (2), where lymph node groups appear coalesced and individual features obscured.

Comparison of Tc-99m dextran with RCL and TCT for sensitivity and specificity would be unproductive for many anatomic sites. Under no clinical circumstance has RCL and only in the detection of appreciably enlarged lymph nodes has TCT had any application to investigation of the internal mammary lymphatics. Radiocolloid lymphoscintigraphy surpasses both these techniques in sensitivity and specificity.

Finally, the potential for lymphoscintigraphy rests with the astute, sound, critical, and informed judgment of individuals—not in reagents.

GÜNEŞ N. EGE
The Princess Margaret Hospital
University of Toronto
Toronto, Ontario

REFERENCES

1. DWORKIN HJ: Teaching Editorial. Potential for lymphoscintigraphy. *J Nucl Med* 23:936-938, 1982
2. HENZE E, SCHELBERT HR, COLLINS JD, et al: Lymphoscintigraphy with Tc-99m labeled dextran. *J Nucl Med* 23: 923-929, 1982

Reply

I thank Dr. Ege for her carefully considered, clarifying response to the referenced Teaching Editorial—"Potential for Lymphoscintigraphy" (1). I trust that the critical reader to whom she refers will be knowledgeable enough to know that contrast media for visualization of efferent and afferent channels of the lymphatic system is delivered in the usual manner, as explained in the next paragraph in the editorial. In the first paragraph, there is no stated or implied alternate route of administration. A similar misinterpretation is displayed later in Dr. Ege's letter, where she comments that, "... , and this agent has found a use *not* in the therapy of metastatic breast carcinoma. . ." At no point is it implied that any of the agents mentioned in the initial portion of that paragraph are used for therapy, and, in fact, it is stated quite plainly that these tracer colloids are used for radionuclide lymphoscintigraphy (RNL). The next sentence in the editorial amplifies this point by offering the ultimate compliment to Dr. Ege's work using antimony colloid by stating that, "A high correlation has been shown between internal mammary RNL and the clinical stage of disease and prognosis." Out of context a quote is misleading, for I quite agree with Dr. Ege's statement that the agent is used in the assessment, treatment planning, and follow-up of patients with breast cancer and malignant melanoma.

When compared with all the diseases of the lymphatic system that might be studied, one is struck by the fact that antimony sulfide colloid has had application only in patients who have breast cancer and malignant melanoma. This finding supports the observation reported in the teaching editorial that the application is narrow, compared with the number of diseases that might be studied. To claim that antimony sulfide colloid has had wide application requires very selective vision. Knowledgeable sources at the Food and Drug Administration in the United States have informed me that fewer than 12 investigators in the United States have ever sought investigational new drug (IND) applications for the use of antimony sulfide colloid for radionuclide lymphoscintigraphy. Under these INDs, approximately 90 hospitals and institutions have been supplied with the material, although most of these users order the material on a sporadic basis only. Apparently, the agent was used by so few investigators in the United States that it was